President Tinubu Appoints Dr. Fatima Zuntu as New NBMA Director-General
President Bola Ahmed Tinubu has officially appointed Dr. Fatima Suleiman Zuntu as the new Director-General and Chief Executive Officer of the National Biosafety Management Agency (NBMA), with the appointment taking effect from April 16, 2026. The announcement was made public on April 20, 2026, through a press statement issued by Chris Ugwuegbulam, Head of Information and Public Relations at the Office of the Secretary to the Government of the Federation. This strategic move aims to strengthen Nigeria's biosafety regulations and oversight in the rapidly evolving field of biotechnology.
Key Responsibilities and Background of Dr. Zuntu
Dr. Zuntu will lead the NBMA, an agency tasked with regulating modern biotechnology practices and ensuring the safe handling, transfer, and use of genetically modified organisms across Nigeria. Her appointment is set for a four-year term, in accordance with Section 5 of the National Biosafety Management Agency Act of 2015. To provide a comprehensive overview, here are seven essential aspects of her career and qualifications:
- Experienced Resident Doctor: Since January 2021, Dr. Zuntu has served as a Resident Doctor at Barau Dikko Teaching Hospital, accumulating five years of hands-on clinical experience that underscores her dedication to patient care and medical excellence.
- Public Health Advocate and Founder: In January 2020, she established the Suleiman Zuntu Foundation, based in Abuja, which focuses on public health initiatives, community service, and improving healthcare access and awareness throughout Nigeria.
- Leadership Role at NNPC HMO: From October 2019 to December 2020, Dr. Zuntu worked as Team Lead for the provider network at NNPC HMO, where she coordinated nationwide provider audits, contracting, and training. A key achievement during this period was developing a model that streamlined issue resolution between healthcare providers and the HMO.
- Medical Officer at the Central Bank of Nigeria: She served as a Medical Officer from May 2018 to March 2019, providing primary healthcare services, prescribing treatments, and enhancing patient record management systems through innovative controls and processes.
- Early Career at National Hospital Abuja: Dr. Zuntu began her medical journey as a House Officer at National Hospital Abuja between January 2017 and January 2018, assisting in surgeries, mentoring over 15 medical students, and promoting health education initiatives.
- Strong Academic Background: She holds a Master's degree in Public Health from the University of South Wales, earned between 2018 and 2020, and a Bachelor of Medicine, Bachelor of Surgery (MBBS) from the University of Maiduguri, completed in 2016.
- Trusted to Lead NBMA: With a diverse background spanning clinical practice, public health advocacy, and healthcare management, Dr. Zuntu is well-positioned to lead the NBMA. Her appointment signals a renewed focus on safety, regulation, and innovation in Nigeria's growing biotechnology sector.
Implications for Nigeria's Biosafety Sector
The appointment of Dr. Fatima Suleiman Zuntu marks a significant step forward for Nigeria's biosafety framework. Her extensive experience in medicine and public health is expected to play a crucial role in ensuring that biotechnology practices are conducted safely and ethically across the country. As Nigeria continues to expand its involvement in genetic modification and related technologies, Dr. Zuntu's leadership will be instrumental in fostering an environment that balances innovation with rigorous safety standards.
This development underscores the Tinubu administration's commitment to appointing qualified professionals to key regulatory positions, aiming to enhance national security and public health in alignment with global best practices. The NBMA, under Dr. Zuntu's guidance, is poised to address challenges and opportunities in the biotechnology landscape, contributing to sustainable development and economic growth in Nigeria.
